Johnson & Johnson (NYSE: JNJ) has disclosed the results from the real-world study on the durability of COVID-19 vaccines in the United States. Results demonstrated that a single shot of the Johnson & Johnson COVID-19 vaccine provided protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Supporting Data
The new study, sponsored by Janssen, a J&J company, evaluated the durability profiles for all three vaccines authorized or approved in the U.S. across three categories; infections, hospitalizations, and ICU admissions.
Per the study, the Johnson & Johnson COVID-19 vaccine remained durable against breakthrough infections and hospitalizations, while the mRNA vaccines (two-doses) showed decreasing effectiveness for both. Notably, all three vaccines demonstrated strong sustained protection against critically severe disease.
Official Comments
EVP, Pharmaceuticals, Janssen Research & Development LLC at Johnson & Johnson, Mathai Mammen, said, “We continue to undertake extensive efforts to study the durability of protection offered by the Johnson & Johnson vaccine amidst the ever-changing COVID-19 pandemic. While these are rapidly evolving data, we are seeing vaccine effectiveness against COVID-19-related hospitalization of approximately 80 percent from a single shot of the Johnson & Johnson vaccine, and this level of protection holds steady across the length of time studied thus far – up to six months. The robust and sustained durability of our COVID-19 vaccine reflects its unique underlying immunology.”
“We previously reported that our vaccine induces a strong antibody response as well as an especially strong increase in T-cells that is consistent across variants, including Omicron,” Mammen added.
Wall Street’s Take
On December 29, Credit Suisse analyst Matt Miksic reiterated a Buy rating and a price target of $200 (16.53% upside potential) on the stock.
Miksic’s updated intra-quarter analysis of October and November sales and scrips at Johnson & Johnson demonstrates $588 million of upside to his estimate for the company’s U.S. pharmaceuticals business.
Consensus among analysts is a Strong Buy based on 6 Buys versus 1 Hold. The average Johnson & Johnson price target of $189.83 implies 10.6% upside potential from current levels. Shares have gained almost 10% over the past year.
Smart Score
Johnson & Johnson scores a “Perfect 10” from TipRanks’ Smart Score rating system. This makes it one of TipRanks’ Top Stocks and implies that the stock has strong potential to outperform market expectations.
Download the TipRanks mobile app now
Related News:
Costco Reports Sales Numbers for December
Pfizer & BioNTech Ink Collaboration Deal to Develop mRNA-based Vaccine for Shingles
Ford’s U.S. Sales Decline; Shares Fall
